Clinical Trials Logo

Liver Diseases clinical trials

View clinical trials related to Liver Diseases.

Filter by:

NCT ID: NCT04778735 Completed - Clinical trials for Liver Transplantation

Investigation of Mortality, Morbidity and Risk Factors After Pediatric Liver Transplantation

Start date: February 24, 2021
Phase: N/A
Study type: Interventional

The Department of Organ Transplantation in Memorial Hospitals has started Pediatric Liver Transplantation Program in 2016. As of the end of 2020, we have performed 169 pediatric liver transplantation. The aim of this study is to investigate the overall mortality, morbidity and risk factors for adverse outcomes in pediatric liver transplantation. The patients' records will be retrospectively scanned and the data will be gathered.

NCT ID: NCT04764305 Recruiting - Liver Diseases Clinical Trials

Liver Disease, Myocardial Fibrosis and Collaterals in the Adult Fontan Patient a Metabolomics and Proteomics Approach

Start date: April 1, 2022
Phase:
Study type: Observational

Out objective is to identify the mechanisms that promote hepatic and myocardial fibrosis, and collateral vessel formation in patients with complex congenital heart disease and Fontan circulation.

NCT ID: NCT04750031 Recruiting - Pain, Acute Clinical Trials

Pain Scores and Complications do Not Differ at Three Recovery Position After Liver Biopsy

Start date: January 1, 2018
Phase:
Study type: Observational

Liver biopsy is still used as the gold standard in the diagnosis of many liver diseases. During the observation after liver biopsy, patients are hospitalized on their right side, which is the biopsy side, with the thought that adverse events (complications) such as bleeding or bile leakage will be less. Patients who do not develop complications after 4-6 hours of observation are discharged home. Some of the patients state that the right side-lying position for 4-6 hours is uncomfortable than the biopsy itself, and they prefer to lie on their back. In our study, researchers aim to investigate the rate of complications after biopsy, what recovery position found more acceptable by the patients.

NCT ID: NCT04732689 Completed - Surgery Clinical Trials

Intraoperative Hemodynamic Management and Postoperative Outcomes in Liver Transplantation

ELIPTO-2
Start date: June 16, 2021
Phase:
Study type: Observational

The overarching objective of the research program entitled ELIPTO (Enhancing Liver Insufficiency and Postoperative Transplantation Outcomes) (www.elipto.ca) is to improve the perioperative care of liver transplant recipients. One of this program's purposes is to better define the effects of intraoperative hemodynamic management on postoperative outcomes in adult liver transplant recipients. In this study, the incidence of postoperative complications within this population will be defined in Canada and France and the association between intraoperative hemodynamics and postoperative outcomes will be measured. Liver transplantation improves the survival of patients with end-stage liver disease (ESLD). It is the second most transplanted organ with a continuously increasing annual number of transplantations, an observation partly explained by an endemic ESLD etiology in the United States, the obesity-related non-alcoholic steatohepatitis (NASH) cirrhosis. In recent decades, although sicker patients are prioritized, survival has improved possibly through an overall improvement in the quality of care. However, postoperative complications have concomitantly increased. On average, liver transplant recipients suffer from more than three postoperative complications, mainly infectious, pulmonary, renal or graft-related, two thirds of them being severe. In a low-risk patients cohort, close to 60% of all patients suffered from at least one severe complication up to 6 months after surgery. Such complications increase mortality, readmissions and cost of care. Organs available for transplantation are a scarce resource; up to 10% of grafts are no longer functional after one year. Interventions that improve patients' postoperative and graft outcomes are needed and few perioperative ones are supported by high-quality evidence.

NCT ID: NCT04718051 Recruiting - Liver Diseases Clinical Trials

S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease

Start date: January 13, 2021
Phase: Phase 4
Study type: Interventional

With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually increased. Although weight loss, dietary adjustments, and certain drug treatments can delay the deterioration of the disease; however, weight loss and dietary adjustment are not easy.

NCT ID: NCT04701567 Recruiting - Liver Diseases Clinical Trials

Diagnostic and Evaluation of Hepato-pancreatico-biliary Disease With MRI

Start date: June 30, 2020
Phase:
Study type: Observational

This is a retrospective review of images from patient data. There is no recruitment necessary for this study. Research Question: Can advanced multiparametric MRI techniques improve the detection and characterization of focal and diffuse liver disease, accurately assess treatment response and predict patient outcomes based on longitudinal monitoring? Hypotheses: Advanced multiparametric MRI techniques improve the detection, characterization and response assessment of focal and diffuse liver disease and can predict serious liver related outcomes.

NCT ID: NCT04675775 Completed - Sarcopenia Clinical Trials

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

Start date: January 21, 2021
Phase: N/A
Study type: Interventional

This study is being completed for patients with cirrhosis, including patients with a prior history of hepatic encephalopathy (HE) to evaluate the feasibility and benefits of medically-tailored meals as an intervention. Patients will be enrolled from the University of Michigan and will complete the baseline assessments in-person or remotely. In addition participants will complete study related materials before, during and after treatment with medically-tailored meals (MTM). After completing the study meals, participants will return for follow-up or have this visit completed remotely as well as have an observational period for 12 more weeks.

NCT ID: NCT04668664 Completed - Liver Cirrhosis Clinical Trials

Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Start date: April 5, 2021
Phase:
Study type: Observational

The objective of the study is to collect and report technical success of direct endoscopic ultrasound guided hepatic and portal vein pressure measurement obtained with EchoTip® Insightâ„¢ in patients with cirrhosis who are referred for an EGD and/or EUS.

NCT ID: NCT04666558 Completed - Cancer Clinical Trials

Heal-Me Personalized Online Nutrition and Exercise Routines

PiONEeR
Start date: November 30, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to compare 12-weeks of virtual multidisciplinary programming provided at three levels of support intensity to determine impacts on clinical outcomes, acceptability, and cost amongst outpatients with cancer, liver disease, or lung disease. Participants will be randomized to one of three groups: (i) standard care, (ii) a personnel-light app-based intervention, (iii) a personnel-intensive app-based intervention. Participants randomized to standard care will receive exercise and nutrition resources as well as a Garmin watch. Participants in the experimental groups will receive standard care, plus a 12-week multidisciplinary app-based personalized program involving 12 weeks of exercise programming and 10-weeks of nutrition programming. Participants in study group 3 will receive additional one-on-one care. The Research Ethics Board at the University of Alberta has approved this study. The protocol will measure patient-related outcome measures including physical function, quality of life, social isolation, and anxiety, as well as measures of acceptability and cost. 216 participants will take part in this study (n=72 per arm). Analyses: fitness testing and patient-reported outcomes will be administered before and after the intervention. Fitness and patient-reported outcomes will be compared using linear mixed models with random effects. App acceptability will be compared between groups using Chi-Square.

NCT ID: NCT04640116 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

Transjugular intrahepatic portosystemic shunt (TIPS) could effectively decrease portal hypertension-related complications. This study intends to evaluate the efficacy and safety of TIPS combined with subsequent microwave ablation in HCC patients with refractory ascites.